A July FDA letter cited Gilead reps for pitching the nucleotide analog Viread as “safer” and “more potent” than similar nucleoside analogs (NRTIs) and ignoring life-threatening side effects like lactic acidosis and kidney and liver problems—issues familiar to NRTIs. “We take [the complaint] very seriously,” said Gilead’s Amy Flood.